Tempus AI (NASDAQ:TEM) Price Target Raised to $80.00

Tempus AI (NASDAQ:TEM) had its price objective upped by equities research analysts at Morgan Stanley from $68.00 to $80.00 in a research note issued on Tuesday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Morgan Stanley’s price objective would suggest a potential upside of 9.07% from the stock’s previous close.

A number of other equities analysts also recently weighed in on the stock. TD Cowen downgraded shares of Tempus AI from a “buy” rating to a “hold” rating and set a $88.00 target price for the company. in a research note on Tuesday, October 21st. Piper Sandler reduced their target price on Tempus AI from $105.00 to $80.00 and set a “neutral” rating for the company in a report on Tuesday. Guggenheim boosted their price objective on Tempus AI from $80.00 to $95.00 and gave the stock a “buy” rating in a research report on Friday, September 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tempus AI in a research report on Wednesday, October 8th. Finally, Cowen downgraded shares of Tempus AI from a “buy” rating to a “hold” rating in a report on Tuesday, October 21st. Seven analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Tempus AI has a consensus rating of “Hold” and an average price target of $80.00.

Tempus AI Trading Up 2.2%

Shares of TEM stock traded up $1.57 on Tuesday, hitting $73.35. The company had a trading volume of 2,290,004 shares, compared to its average volume of 11,407,801. Tempus AI has a twelve month low of $31.36 and a twelve month high of $104.32. The company has a debt-to-equity ratio of 2.45, a quick ratio of 3.12 and a current ratio of 3.28. The firm has a market cap of $12.74 billion, a P/E ratio of -61.71 and a beta of 4.86. The stock’s 50-day moving average is $85.83 and its two-hundred day moving average is $71.30.

Tempus AI (NASDAQ:TEM) last announced its earnings results on Tuesday, November 4th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.05. Tempus AI had a negative return on equity of 73.21% and a negative net margin of 18.45%.The business had revenue of $334.21 million for the quarter, compared to analysts’ expectations of $328.89 million. During the same period in the prior year, the business posted ($0.46) earnings per share. The firm’s revenue was up 84.7% on a year-over-year basis. Tempus AI has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that Tempus AI will post -6.15 earnings per share for the current fiscal year.

Insider Transactions at Tempus AI

In other Tempus AI news, Director Theodore Leonsis sold 44,000 shares of the company’s stock in a transaction dated Wednesday, August 13th. The stock was sold at an average price of $69.90, for a total value of $3,075,600.00. Following the transaction, the director directly owned 86,756 shares in the company, valued at $6,064,244.40. This represents a 33.65% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Ryan Fukushima sold 17,460 shares of Tempus AI stock in a transaction dated Tuesday, August 19th. The shares were sold at an average price of $74.65, for a total value of $1,303,389.00. Following the sale, the chief operating officer owned 839,180 shares of the company’s stock, valued at approximately $62,644,787. This trade represents a 2.04% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 1,105,282 shares of company stock worth $87,726,381. 26.27% of the stock is owned by corporate insiders.

Institutional Trading of Tempus AI

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. increased its stake in Tempus AI by 22.1% in the third quarter. Vanguard Group Inc. now owns 9,441,607 shares of the company’s stock valued at $762,032,000 after acquiring an additional 1,706,837 shares during the last quarter. ARK Investment Management LLC increased its position in shares of Tempus AI by 35.9% during the 1st quarter. ARK Investment Management LLC now owns 7,501,399 shares of the company’s stock valued at $361,867,000 after purchasing an additional 1,981,755 shares during the last quarter. Nikko Asset Management Americas Inc. raised its stake in shares of Tempus AI by 31.5% during the first quarter. Nikko Asset Management Americas Inc. now owns 4,260,553 shares of the company’s stock worth $205,401,000 after acquiring an additional 1,021,460 shares in the last quarter. AQR Capital Management LLC bought a new position in shares of Tempus AI during the second quarter valued at approximately $54,020,000. Finally, CloudAlpha Capital Management Limited Hong Kong purchased a new stake in Tempus AI in the first quarter worth $34,119,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.